Skip to main content

Table 1 Group and subgroup description

From: The effect of 8 weeks of treatment with transcranial pulsed electromagnetic fields on hand tremor and inter-hand coherence in persons with Parkinson’s disease

 

Group

N

N, females

Age (years)

Disease duration (years)

LED (mg/day)

UPDRS total

UPDRS motor

UPDRS hand tremor

PD, rest

 All

T-PEMF

22

11

68 (6)

6 (5)

547 (439)

49 (15)

28 (9)

3 (2)

 

Placebo

14

6

63 (12)

3 (2)

399 (234)

43 (13)

25 (9)

3 (2)

 Unilateral

T-PEMF

11

7

69 (5)

5 (5)

562 (470)

41 (12)

23 (8)

2 (1)

 

Placebo

9

4

62 (14)

3 (2)

405 (271)

41 (10)

24 (8)

2 (1)

 Bilateral

T-PEMF

11

4

67 (7)

7 (5)

531 (427)

57 (12)

33 (8)

5 (2)

 

Placebo

5

2

65 (4)

3 (2)

389 (176)

46 (17)

27 (11)

4 (3)

PD, postural

 All

T-PEMF

23

10

67 (6)

5 (5)

520 (440)

46 (16)

26 (10)

3 (2)

 

Placebo

20

9

63 (11)

4 (3)

474 (346)

46 (14)

26 (9)

3 (2)

 Unilateral

T-PEMF

9

5

67 (6)

2 (2)

380 (402)

38 (11)

22 (7)

2 (1)

 

Placebo

13

6

62 (12)

4 (3)

436 (264)

43 (13)

25 (8)

2 (1)

 Bilateral

T-PEMF

14

5

67 (7)

7 (5)

616 (455)

52 (18)

29 (11)

4 (2)

 

Placebo

7

3

63 (10)

4 (2)

545 (480)

50 (18)

29 (11)

3 (3)

REF

 

40

19

66 (8)

  1. Baseline descriptive variables for Parkinson’s disease (PD) tremor groups, subgroups and the reference group (REF) according to treatment allocation. Disease duration reflects the number of whole years from the time of diagnosis to inclusion. Levodopa equivalent dose (LED) was calculated according to Tomlinson et al. 2010 [43]. The Unified Parkinson’s Disease Rating Scale (UPDRS) hand tremor score reflects the sum of scores for rest and postural hand tremor (item 20.2–3 and 21.1–2). Variables are presented as mean (SD)